throbber
Highly Confidential
`
`Page 318
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
` CASE NO.: IPR2015-00990
` Patent: 7,056,886
`COALITION FOR AFFORDABLE DRUGS, II, LLC,
` Petitioner,
`vs.
`NPS PHARMACEUTICALS, INC.,
` Patent Owner.
`--------------------------------------------------------
` VIDEO DEPOSITION
` OF
` ANTHONY PALMIERI, III, Ph.D.
` taken on behalf of the Patent Owner
` pursuant to a Notice of Taking Deposition
` HIGHLY CONFIDENTIAL - Attorneys Eyes Only
`
` DATE: Wednesday, May 11, 2016
` TIME: 9:18 a.m.
` PLACE: Hilton Conference Center
` 1714 Southwest 34th Street
` Gainesville, Florida
` REPORTER: Ingrid T. Cox, RPR
` Notary Public, State of Florida at Large
` Job no. 107130
`
`TSG Reporting - Worldwide 877-702-9580
`
`1 2
`
`3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 1
`
`NPS Ex. 2171
`CFAD v. NPS
`IPR2015-01093
`
`

`
`Highly Confidential
`
`Page 319
`
`APPEARANCES:
`
` MATTHEW FEDOWITZ, ESQUIRE
` Merchant & Gould
` 1701 Duke Street
` Alexandria, Virginia 22314
` Attorneys for Petitioner.
`
` JOSEPH ROBINSON, ESQUIRE
` HEATHER MOREHOUSE ETTINGER, ESQUIRE
` Troutman Sanders
` 875 Third Avenue
` New York, New York 10022
` Attorneys for Patent Owner.
`
`ALSO PRESENT:
`JACK LUBRANT, Videographer
`
` I N D E X
`WITNESS: PAGE
`ANTHONY PALMIERI, III, Ph.D.
` Examination by Mr. Robinson 324
`
`TSG Reporting - Worldwide 877-702-9580
`
`1 2 3
`
`4 5
`
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 2
`
`

`
`Highly Confidential
`
`Page 320
`
` E X H I B I T S
`NUMBER PAGE
`Composite Exhibit 2500
`(Reply Declaration) 324
`Exhibit 2501
`(Pharmaceutical Education) 326
`Exhibit 2502
`(Dissolution of Suppositories V) 328
`Exhibit 2503
`(Dissolution of Suppositories IV) 331
`Exhibit 2504
`(Portrait of Rocky Mountain Drug Wholesaling) 331
`Exhibit 2505
`(Dissolution of Suppositories III) 331
`Exhibit 2506
`(Pharmaceutical Technology) 331
`Exhibit 2507
`(Medical Incidents) 331
`Exhibit 2508
`(Drug Development and Industrial Pharmacy) 331
`Exhibit 2509
`(Microencapsulation and Dissolution) 331
`Exhibit 2510
`(A Model for Multivariate Prediction) 331
`Exhibit 2511
`(An Undergraduate Experiment) 331
`Exhibit 2512
`(Drug Therapy at a Frontier Fort Hospital) 331
`Exhibit 2513
`(Effect of Dissolved Oxygen Levels) 331
`Exhibit Number 2514 - no exhibit marked
`
`TSG Reporting - Worldwide 877-702-9580
`
`12
`
`3
`4
`
`5
`
`6
`7
`
`8
`
`9
`10
`
`11
`
`12
`13
`
`14
`
`15
`16
`
`17
`
`18
`19
`
`20
`
`21
`22
`
`23
`
`24
`25
`
`Page 3
`
`

`
`Highly Confidential
`
`Page 321
`
` E X H I B I T S (cont.)
`NUMBER PAGE
`Exhibit 2515
`(Dissolution of Prednisone Microcapsules) 331
`Exhibit 2516
`(Production of a Coacervate Film) 331
`Exhibit 2517
`(Multivariate Prediction of Academic Success) 331
`Exhibit 2518
`(A Student Experiment in Biopharmaceutics) 331
`Exhibit 2519
`(Scholarly Open Access article) 336
`Exhibit 2520
`(WO 98/25955) 353
`Exhibit 2521
`(Label for GATTEX) 423
`Exhibit 2522
`(Protein Therapeutics) 492
`Exhibit 2523
`(Definition of well versed) 510
`Exhibit 2524
`(Figure 3) 513
`Exhibit 2525
`(History and Development of Incretin Therapy) 518
`Exhibit 2526
`(Citation: CFR 445 1999) 539
`Exhibit 2527
`(Definition of micelle) 548
`Exhibit 2528
`(Investigation of Histidine) 645
`Exhibit 2529
`(DHEA Sulfate) 659
`
`TSG Reporting - Worldwide 877-702-9580
`
`12
`
`3
`
`4
`5
`
`6
`
`7
`8
`
`9
`
`10
`11
`
`12
`
`13
`14
`
`15
`
`16
`17
`
`18
`
`19
`20
`
`21
`
`22
`23
`
`24
`
`25
`
`Page 4
`
`

`
`Highly Confidential
`
`Page 322
`
` E X H I B I T S (cont.)
`NUMBER PAGE
`Exhibit 2530
`(Particulate Matter in Injections - 1985) 692
`
`Exhibit 2531
`(Particulate Matter in Injections - 2000) 695
`
` REPORTER'S KEY TO PUNCTUATION:
`
` -- At the end of question or answer references
` interruption.
` ... References a trail-off by the speaker. No
` testimony was omitted.
`
` "Uh-huh" References an affirmative sound.
`
` "Uh-uh" References a negative sound.
`
`TSG Reporting - Worldwide 877-702-9580
`
`12
`
`3
`4
`
`5
`
`6
`
`789
`
`10
`11
`
`12
`
`13
`14
`
`15
`
`16
`
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Page 5
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`Highly Confidential
`
`Page 323
`
` ANTHONY PALMIERI, III, Ph.D.
` VIDEOGRAPHER: Time on the video record 9:18
`a.m. Today's date May 11th, 2016. My name is Jack
`Lubrant representing Veritext. This deposition is
`being held at the Hilton, 1714 34th Street,
`Gainesville, Florida. It's being taken by counsel
`for the defense. The caption of the case is
`Coalition for Affordable Drugs, II, LLC, versus NPS
`Pharmaceuticals, Inc., U.S. Patent and Trademark
`Office, Case Number IPR2015-00990, 01093, Patent
`7,056,886. This deposition is of Dr. Anthony
`Palmieri.
` At this time the attorneys present in the room
`will identify themselves for the record. Then our
`court reporter, Ingrid Cox, will swear in the
`witness.
` MR. FEDOWITZ: Matthew Fedowitz, on behalf of
`petitioner, from Merchant & Gould in Washington.
` MR. ROBINSON: Joseph Robinson and Heather
`Ettinger on behalf of NPS Pharmaceuticals from
`Troutman Sanders.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 6
`
`

`
`Highly Confidential
`
`Page 324
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`Thereupon,
` ANTHONY PALMIERI, III, Ph.D.,
`having been first duly sworn, testified as follows:
` EXAMINATION
`BY MR. ROBINSON:
` Q. Dr. Palmieri, we've had the pleasure of having
`one deposition already so I guess you remember the
`rules?
` A. It's always good to go over them again, but I
`think I do, but let's be sure.
` Q. Sure. I'll ask you questions. You can answer
`the questions. If your counsel objects you still need
`to answer the question unless he instructs you not to
`answer the question.
` A. I understand.
` Q. I'm going to show you -- I'll introduce a copy of
`your reply declaration and these IPRs. This is the one
`from IPR01090 of the declarations that were essentially
`identical.
` MR. FEDOWITZ: This is all the exhibits also?
` MS. ETTINGER: Yes.
` MR. ROBINSON: All the exhibits.
` MR. FEDOWITZ: Great. Thanks a lot.
` (Composite Exhibit 2500 was marked for
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 7
`
`

`
`Highly Confidential
`
`Page 325
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`Identification.)
`BY MR. ROBINSON:
` Q. Do you recognize Exhibit 2500?
` A. I believe so. It appears to be, without going
`through every page, a copy of my -- one of my reply
`reports, there were two, and also a number of exhibits.
` Q. Let's turn to Exhibit 1002 of Composite
`Exhibit 2500, and that is your CV, correct?
` A. That was the CV -- that is an earlier copy of my
`CV. I retired June 30th of 2015 and I believe that I
`referenced that in my reply report. But it's the same
`except I'm now retired and I'm an adjunct faculty member
`in pharmaceutics.
` Q. Take a look at page seven of Exhibit 1002,
`please.
` A. Yes.
` Q. That's a list of publications one through 19,
`correct?
` A. Yes. That is a list of what we refer to as
`refereed publications.
` Q. Let me show you -- just a second. Pages seven
`through eight of your CV list your publications,
`correct?
` A. Page -- beginning on page seven lists my
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 8
`
`

`
`Highly Confidential
`
`Page 326
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`refereed publications, those being articles that have
`been published in refereed journals. The rest of
`page eight and continuing onto page nine are different
`books and chapters in books that I've written, yes.
` Q. Okay. I'll show you what we're going to mark as
`Exhibit 2501.
` (Exhibit 2501 was marked for
`Identification.)
`BY MR. ROBINSON:
` Q. Do you recognize this publication?
` A. I certainly do.
` Q. What is it?
` A. The title of the publication is Intellectual
`Property and the Pharmaceutical Scientist - A View From
`the Other Side. This was -- this appeared in the
`American Journal of Pharmaceutical Education in 1989.
` Q. Is article 2501 on obviousness under 35USC103?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
`BY MR. ROBINSON:
` Q. Does article 2501 discuss obviousness under
`35USC103?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 9
`
`

`
`Highly Confidential
`
`Page 327
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` THE WITNESS: This publication was over 25 years
` ago. I would have to review the publication.
`BY MR. ROBINSON:
` Q. Go ahead.
` A. And your question is does this article -- what is
`your question again?
` Q. Does this article discuss obviousness under
`35USC103?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I have read the article through.
` And I need your question back, please.
`BY MR. ROBINSON:
` Q. Does this article discuss obviousness under
`35USC103?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I am not a lawyer. I see nowhere
` in here that it refers to the document that you cite
` about obviousness, so I don't think it does, unless
` you want to point out a specific place.
`BY MR. ROBINSON:
` Q. Okay. Exhibit 2501 corresponds to article one on
`page seven of your CV in Exhibit 2500, correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 10
`
`

`
`Highly Confidential
`
`Page 328
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` A. That is correct.
` Q. Okay. Does Exhibit 2501 discuss formulation of
`peptides?
` A. No.
` Q. Does Exhibit 2501 discuss stabilization of
`peptides?
` A. No.
` Q. Does Exhibit 2501 discuss lyophilization of
`peptides?
` A. No.
` Q. Does Exhibit 2501 discuss degradation of
`peptides?
` A. No.
` Q. Does 2501 discuss glucagon?
` A. No.
` Q. Does Exhibit 2501 discuss GLP-2?
` A. No.
` Q. Does Exhibit 2501 discuss GLP-2 analogs?
` A. No.
` MR. ROBINSON: We're going to mark this as
` Exhibit 2502.
` (Exhibit Number 2502 was marked for
`Identification.)
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 11
`
`

`
`Highly Confidential
`
`Page 329
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`BY MR. ROBINSON:
` Q. Do you recognize Exhibit 2502?
` A. Certainly.
` Q. What is it?
` A. This is an article published in 1986 in a
`refereed journal, Drug Development and Industrial
`Pharmacy, the title of which is Dissolution of
`Suppositories V: Influence of Aging on Aspirin Release
`From Polyethyleneglycol Suppositories With and Without
`Crospovidone.
` Q. Okay. And Exhibit 2502 corresponds to article
`number two on page seven of your CV, correct?
` A. I believe that's correct, yes.
` Q. Does Exhibit 2502 discuss formulation of
`peptides?
` A. No.
` Q. Does Exhibit 2502 discuss stabilization of
`peptides?
` A. No.
` Q. Does Exhibit 2502 discuss lyophilization of
`peptides?
` A. No.
` Q. Does Exhibit 2502 discuss degradation of
`peptides?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 12
`
`

`
`Highly Confidential
`
`Page 330
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` A. No.
` Q. Does Exhibit 2502 discuss glucagon?
` A. No.
` Q. Does Exhibit 2502 discuss GLP-2?
` A. No.
` Q. Does Exhibit 2502 discuss GLP analogs?
` A. No.
` Q. Does Exhibit 2502 -- I'm sorry. I'll cut this
`short. Do any of the articles one through 19 on pages
`seven through eight of your CV discuss the formulation
`of peptides?
` MR. FEDOWITZ: Objection. There's no document in
` front of him.
`BY MR. ROBINSON:
` Q. I'll give you all the documents, I'll go
`through them one by one.
` MR. FEDOWITZ: Yeah. I think if we want to
` introduce them as one group or something just so he
` can take a look at them. Whatever the official way
` to do it would be.
` MR. ROBINSON: Sure. Okay. Let's introduce --
` we'll mark as Exhibit 2502 -- or is it -- 2503.
` MR. FEDOWITZ: Do you want to introduce them all
` as one exhibit?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 13
`
`

`
`Highly Confidential
`
`Page 331
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. ROBINSON: I'll introduce them separately so
` that when he's referring to them he can refer to them
` separately, but then I'll ask a group question. I
` think that's the easier way to do it.
` (Exhibit 2503 was marked for
`Identification.)
` MR. FEDOWITZ: Is this 2503?
` MR. ROBINSON: Yes. 2504, 2505, 2506, 2507,
` 2508, 2509, 2510, 2511, 2512, 2513. This is 2514.
` This is 2515.
` (Exhibits 2504 through 2518 were marked for
`Identification.)
` MR. FEDOWITZ: Did you give me yours?
` MR. ROBINSON: If you want it you can have it.
` MR. FEDOWITZ: Is it 2511 or is it 2513?
` MR. ROBINSON: 2511 is the 1979 article
` MR. FEDOWITZ: Biopharmaceuticals?
` MR. ROBINSON: Yeah, Undergraduate Experiment in
` Biopharmaceuticals.
` MR. FEDOWITZ: Okay.
` MR. ROBINSON: This is 2518.
` MR. FEDOWITZ: Yeah. You keep yours. I need
` Number 13. Excuse me, I have -- is this 13? Oh,
` okay. This is 2512.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 14
`
`

`
`Highly Confidential
`
`Page 332
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. ROBINSON: What's the name of it?
` MR. FEDOWITZ: Drug Therapy at a Frontier Fort.
` MR. ROBINSON: Yeah, 2512. This is 2515.
` MR. FEDOWITZ: Well, I need 13.
` THE WITNESS: My 13 and 14 --
` MR. FEDOWITZ: I don't have those two.
` THE WITNESS: 13 and 14 in my hands here seem to
`be the same document.
` MR. ROBINSON: Let's take a look.
` THE WITNESS: They certainly have the same title.
` MR. ROBINSON: Oh, you know what, that's probably
`your 13.
` THE WITNESS: Do you want to make it 13 or 14?
` MR. FEDOWITZ: So which one do we want to call --
`what is this one?
` MR. ROBINSON: 13 is the Pharmaceutical Science,
`1978.
` MR. FEDOWITZ: Okay. So this is 14.
`Pharmaceutical Science. These two are the same.
` MR. ROBINSON: Which two?
` MR. FEDOWITZ: 13 and -- well, I think one of
`those is mine.
` MR. ROBINSON: This is 13. This is your 13.
`Then we have 14, which is Canadian Pharm. That is
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 15
`
`

`
`Highly Confidential
`
`Page 333
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` marked at 15. We'll leave it at 16. This is 16.
` This is 17. This is 18.
`BY MR. ROBINSON:
` Q. Dr. Palmieri, do you recognize Exhibits 2502
`through 2518?
` A. They appear to be copies of articles that I have
`written. Understanding that I think we skipped one
`number, but the documents that you have given me as
`exhibits appear to be copies of my refereed
`publications.
` Q. Okay. Do any of your refereed publications
`discuss formulation of peptides?
` MR. FEDOWITZ: Objection. I'll represent that
` this is not a comprehensive set of exhibits for all
` of Dr. Palmieri's publications.
` MR. ROBINSON: I'm looking at his CV right now.
`BY MR. ROBINSON:
` Q. Do any of your refereed publications on
`page seven or eight concern the formulation of peptides?
` A. Under -- on my CV on pages seven and eight
`concerning refereed publications, as I recall in looking
`at them again, they do not include formulation of
`peptides.
` Q. Do any of your refereed publications on pages
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 16
`
`

`
`Highly Confidential
`
`Page 334
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`seven and eight of your CV discuss stabilization of
`peptides?
` A. Not that I recall.
` Q. Do any of those publications discuss
`lyophilization of peptides?
` A. Not that I recall.
` Q. Do any of those publications discuss degradation
`of peptides?
` MR. FEDOWITZ: Objection.
` THE WITNESS: Not that I recall.
`BY MR. ROBINSON:
` Q. Do any of those publications discuss glucagon?
` A. Not that I recall.
` Q. Do any of those publications discuss GLP-2?
` A. Not that I recall.
` Q. Do any of those publications discuss GLP-2
`analogs?
` A. Not that I recall.
` Q. What does the history of pharmacy have to do with
`the present IPRs?
` A. I don't understand the question.
` Q. Is the history of pharmacy related to the present
`IPRs?
` A. You ask a very -- use a very diffuse term, the
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 17
`
`

`
`Highly Confidential
`
`Page 335
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`history of pharmacy.
` Q. Well, you use that term in your declaration,
`don't you?
` A. Correct. Part of my interest is in history of
`pharmacy, yes.
` Q. What does the history of pharmacy have to do with
`the present IPRs?
` A. I still don't -- I don't understand the question.
`You have to rephrase it or --
` Q. Is the history of pharmacy relevant to the
`present IPRs?
` MR. FEDOWITZ: Objection.
` THE WITNESS: Again, you ask a very broad -- you
` use the phrase history of pharmacy. I...
`BY MR. ROBINSON:
` Q. You say that I'm the author of over 80
`publications and presentations on pharmaceutics,
`intellectual property, dosage forms, dissolutions,
`pharmacy education and the history of pharmacy. That's
`on paragraph five of your declaration, CFAD,
`Exhibit 1041. Now, I want to know what history of
`pharmacy has to do with present IPRs?
` A. You read it correctly. In paragraph five of my
`declaration I state I am the author of over 80
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 18
`
`

`
`Highly Confidential
`
`Page 336
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`publications and presentations on pharmaceutics,
`intellectual property, dosage forms, dissolutions,
`pharmacy education and the history of pharmacy.
` Q. Okay. And I want to know if the history of
`pharmacy is relevant to the present IPRs.
` A. In general the history of pharmacy, which would
`include pharmaceutical patents, would be relevant.
` Q. I'll show you what we're going to mark as
`Exhibit 2519.
` (Exhibit 2519 was marked for
`Identification.)
` MR. FEDOWITZ: Joe, are we going back to these?
` Did you say 2519?
` MR. ROBINSON: Yes.
`BY MR. ROBINSON:
` Q. Do you know of Scholarly Open Access?
` A. I've never seen this document, no.
` Q. This article is from website
`HTTPS://scholarlyOA.com/individual-journals/. Could you
`please read the first paragraph under potential possible
`or probable predatory scholarly open access journals?
` A. I believe what you're referring to is the
`following: This is a list of questionable scholarly
`open access standalone journals. For journals published
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 19
`
`

`
`Highly Confidential
`
`Page 337
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`by a publisher please look for the publisher on the list
`of publishers here (HTTPS://scholar -- excuse me,
`scholarlyOA.com/publishers/). This list is only for
`single standalone journals.
` Q. Okay. And let's take a look at your CV again.
`It's Exhibit 1002. And in Exhibit 1002, page five, it
`says that you're a member of the editorial advisory
`board of the Journal of Chemical and Pharmaceutical
`Sciences, correct?
` A. It does state that I am the editorial -- I am a
`member of the editorial advisory board and I -- I'm
`sorry, I don't recall which one you mentioned.
` Q. Journal of Chemical and Pharmaceutical Sciences.
` A. Yes, I see that.
` Q. And it says also that you're a member of the
`editorial advisory board of the Research Journal of
`Pharmaceutical, Biological and Chemical Sciences,
`correct?
` A. I see that, yes.
` Q. And on the list attached to Exhibit 2519 of
`questionable scholarly open access standalone journals
`the list includes Journal of Chemical and Pharmaceutical
`Sciences, correct?
` MR. FEDOWITZ: Objection.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 20
`
`

`
`Highly Confidential
`
`Page 338
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` THE WITNESS: What page are you pointing to.
`BY MR. ROBINSON:
` Q. 26.
` A. And what was the journal again?
` Q. Chemical and Pharmaceutical Research.
` A. That is on there, yes.
` Q. Yes. And the list in Exhibit 2519 of
`questionable scholarly open access standalone journals
`also includes the Research Journal of Pharmaceutical,
`Biological and Chemical Sciences, correct?
` MR. FEDOWITZ: Objection to the characterization
` of whatever this website is. What page are you
` looking at?
` MR. ROBINSON: Page 31.
` THE WITNESS: It's on this list, yes. This is
` the first time I've seen this list.
`BY MR. ROBINSON:
` Q. Okay.
` A. Again, I've never seen that document before.
` Q. Now, some of the publications that we discussed
`earlier in your CV on pages seven to eight discuss
`intellectual property, correct?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 21
`
`

`
`Highly Confidential
`
`Page 339
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` THE WITNESS: The number one refereed
` publications is titled Intellectual Property and the
` Pharmaceutical Scientist - A View From the Other
` Side. That was an article that was published in the
` journal and also a presentation to academicians. I
` believe that's the only one that talks about
` intellectual property.
`BY MR. ROBINSON:
` Q. And you were an intellectual property liaison at
`some time during your career, correct?
` A. When I was at Upjohn I was in the research and
`development group at the Upjohn company in Kalamazoo and
`one of my titles was -- I had a number of titles. One
`of them was patent liaison.
` Q. And what were your duties as patent liaison at
`Upjohn?
` A. My duties would vary from throughout my 15 years
`or so at the Upjohn Company. I was hired in 1985, as I
`recall, and I had the title senior patent liaison
`scientist. My responsibilities as part of a scientist
`in the research and development division included
`talking to scientists about their experiments because I
`was recognized as a person with knowledge in that area.
`It also included being a member of project teams for
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 22
`
`

`
`Highly Confidential
`
`Page 340
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`drug development along with other team members. And it
`also -- part of it was to be, as the name implies, if
`there was -- if the project team had a question that we
`needed a lawyer to handle I was the person that would
`discuss that with the lawyers.
` Q. Okay. And as a patent liaison you're aware that
`an inventor does not need to include everything in a
`patent specification that he considered in making his
`invention, correct?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I don't know that. I'm not a
` lawyer.
`BY MR. ROBINSON:
` Q. Are you aware that an inventor does not need to
`include what was know in the prior art in a patent
`specification?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I'm not a lawyer. I don't know
` that.
`BY MR. ROBINSON:
` Q. Okay. Are you aware that an inventor does not
`need to include examples in a patent specification?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 23
`
`

`
`Highly Confidential
`
`Page 341
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I'm not a lawyer. I don't know the
` answer to that.
`BY MR. ROBINSON:
` Q. Are you aware that a specification need only set
`forth what the applicant regards as his invention with
`sufficient particularity and distinctiveness?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: Would you repeat the question?
`BY MR. ROBINSON:
` Q. Are you aware that a patent specification need
`only set forth what the applicant regards as his
`invention with particularity and distinctness?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I'm not a lawyer. I don't know the
` answer to that. That's why I would talk to the
` lawyers. I am not a lawyer.
`BY MR. ROBINSON:
` Q. Let me show you what we've previously marked as
`Exhibit 1003. That's U.S. patent number 7,056,886.
` MR. FEDOWITZ: This is the same one.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 24
`
`

`
`Highly Confidential
`
`Page 342
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. ROBINSON: Okay. Yeah, I'm going to
` introduce them separately.
` THE WITNESS: What is the -- I prefer to use the
` one in the binder since there's not a staple. Yes.
`BY MR. ROBINSON:
` Q. The 886 patent does not claim the characteristics
`of GLP-2, correct?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I don't understand the question.
`BY MR. ROBINSON:
` Q. Okay. What are the characteristics of GLP-2?
` MR. FEDOWITZ: Objection.
` THE WITNESS: That's a different question than
` you asked previously.
`BY MR. ROBINSON:
` Q. Let's make it easy, okay? Let's go to
`paragraph nine --
` A. Okay.
` Q. -- of your declaration. And in paragraph nine on
`page four, first bullet, you refer to the
`characteristics of GLP-2 or analogs thereof. What are
`the characteristics of GLP-2 or analogs thereof to which
`you're referring to?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 25
`
`

`
`Highly Confidential
`
`Page 343
`
` ANTHONY PALMIERI, III, Ph.D.
` A. I'm sorry, I can't find the bullet point.
` Q. I'm sorry. Paragraph ten, first bullet.
` A. Paragraph ten.
` Q. Paragraph ten, first bullet, page four, you refer
`to the characteristics of GLP-2 or analogs thereof.
`What I'd like to know is what characteristics of GLP-2
`or analogs thereof you're referencing.
` A. Paragraph -- bear with me for a minute, please.
`Paragraph ten, first bullet?
` Q. Right. I'm referring to Exhibit 1041.
` MR. FEDOWITZ: Do you want to point him to it?
` MR. ROBINSON: Yeah.
` THE WITNESS: Right. I talk about this and the
` statement reads, paragraph ten, first bullet, "The
` inventor of the 886 patent did not consider the
` characteristics of GLP-2 or analogs thereof that Dr.
` Carpenter discusses at length as complexities in
` formulating proteins and peptides despite the claims
` encompassed in a large number, for example, thousands
` of GLP-2 analogs. Therefore, they shouldn't be
` considered complexities now just because Dr.
` Carpenter says so."
` That's the statement.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 26
`
`

`
`Highly Confidential
`
`Page 344
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
`BY MR. ROBINSON:
` Q. You read it correctly. And now I'm asking you
`what are the characteristics of GLP-2 or analogs thereof
`to which you're referencing?
` MR. FEDOWITZ: Objection.
` THE WITNESS: I'm referring to ones that Dr.
` Carpenter discussed in that where Dr. Carpenter
` discusses the number of different reactions that can
` occur, the number of different physical chemical
` parameters there, is what -- I'm replying, if you
` will, to what Dr. Carpenter states.
`BY MR. ROBINSON:
` Q. Okay. And the 886 patent does not claim the
`number of different reactions that can occur that you
`just referenced, correct?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I don't -- I don't understand the
` question.
`BY MR. ROBINSON:
` Q. Does -- do you know where the claims are of the
`886 patent?
` A. Certainly they begin on com 12, line
`approximately eight.
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 27
`
`

`
`Highly Confidential
`
`Page 345
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` Q. Can you show me which claim of the 886 patent
`claims the number of different reactions that can occur
`with respect to GLP-2?
` MR. FEDOWITZ: Objection, calls for a legal
` conclusion.
` THE WITNESS: I don't recall seeing any number of
` reactions. However, again, that would call for a
` legal conclusion.
`BY MR. ROBINSON:
` Q. Can you show me where -- which claim of the 886
`patent claims a number of different reactions that can
`occur with respect to any GLP-2 analogs?
` MR. FEDOWITZ: Objection, legal conclusion.
` THE WITNESS: Again, that's a legal conclusion
` and I cannot answer that question.
`BY MR. ROBINSON:
` Q. You can take a look at the claims and show me if
`you find it.
` MR. FEDOWITZ: Same objection.
` THE WITNESS: I need the question again, please.
`BY MR. ROBINSON:
` Q. Sure. Can you show me which claim of the 886
`patent claims a number of different reactions that can
`occur with respect to GLP-2 analogs?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 28
`
`

`
`Highly Confidential
`
`Page 346
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. FEDOWITZ: Objection. Same objection.
` THE WITNESS: These are mostly formulation
` claims, not react claims involving reactions, as I
` read it from my nonlegal standpoint.
`BY MR. ROBINSON:
` Q. Can you show me which claims of the 886 patent
`claim the chemical -- chemical physical properties of
`GLP-2?
` MR. FEDOWITZ: Same objection.
` THE WITNESS: Again, I'm looking at it from a
` science standpoint, not a legal standpoint. I would
` read these mostly as formulation claims. This is a
` formulation number of claims.
`BY MR. ROBINSON:
` Q. Can you show me which of the claims of the 886
`patent claim the chemical physical parameters of GLP-2
`analogs?
` MR. FEDOWITZ: Same objection.
` THE WITNESS: Could you repeat the question,
` please?
`BY MR. ROBINSON:
` Q. Can you show me which of the claims of the 886
`patent claim the chemical physical parameters or
`properties of GLP-2 analogs?
`
`TSG Reporting - Worldwide 877-702-9580
`
`Page 29
`
`

`
`Highly Confidential
`
`Page 347
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` ANTHONY PALMIERI, III, Ph.D.
` MR. FEDOWITZ: Same objection.
` THE WITNESS: Again, these appear to be from a
` nonlegal standpoint, and I am not a lawyer, these
` appear to be formulation or simulated formulation
` cases -- claims. I'm not a lawyer. So no.
`BY MR. ROBINSON:
` Q. Okay. Can you show me which 886 patent claim
`claims the complexities to which you refer in
`paragraph ten, first bullet, of your declaration?
` MR. FEDOWITZ: Same objection.
` THE WITNESS: And the same answer

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket